Stella Diagnostics (Stella Diagnostics) Beginning Cash Position : $0.00 Mil (As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Stella Diagnostics Beginning Cash Position?

Stella Diagnostics's Beginning Cash Position for the quarter that ended in Sep. 2023 was $0.00 Mil.

Stella Diagnostics Beginning Cash Position Historical Data

The historical data trend for Stella Diagnostics's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stella Diagnostics Beginning Cash Position Chart

Stella Diagnostics Annual Data

Trend

Beginning Cash Position

Stella Diagnostics Quarterly Data
	Sep22	Sep23
Beginning Cash Position	-	-

Stella Diagnostics Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

Stella Diagnostics Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of Stella Diagnostics's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Stella Diagnostics (Stella Diagnostics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Stella Diagnostics Inc (OTCPK:SLDX) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

N/A

Address

50 West Broadway, Suite 300, Salt Lake City, UT, USA, 84104

Website

https://www.stelladx.com

Stella Diagnostics Inc is a molecular diagnostics-based organization focused on improving patient management strategies for people living with severe esophageal disease. It is developing first-line diagnostic tools that provide superior molecular information for providers as compared to the current standard screening protocols.